Russian Heart Failure Journal 2009year Insulin resistance syndrome and CHF: an unsolved problem

To access this material please log in or register

Register Authorize

Insulin resistance syndrome and CHF: an unsolved problem

Bylova N. A., Dzidzariya M. I.



Insulin resistance is defined as a disturbed metabolic response to exogenous or endogenous insulin. Insulin resistance results in increased insulin levels in blood plasma compared to those required for the available level of glucose. Chronic heart failure is currently one of the most severe and prognostically unfavorable cardiovascular diseases. Chronic heart failure is a progressive syndrome, and patients with asymptomatic CHF may proceed to a group of the most severely ill non-responders within 1-5 years. Insulin resistance may be present in CHF both as minimal changes (predisposition to hypo- or hyperglycemia; “flattened” glycemic curve) and as impaired resting glucose tolerance or DM. At present time, there is no unambiguous opinion on the correction of insulin resistance syndrome in patients with CHF. Considering the growing population of patients with DM and CHF, there is a need for a special (desirably randomized) trial to define an optimal antidiabetic therapy for patients with CHF and DM with respect of both glycemic control and the effect on their morbidity and mortality.
  1. Granberry MC, Fonseca VA. Insulin resistance syndrome: options for treatment. South Med J. 1999; 92 (1):2–15.
  2. Балаболкин М. И, Дедов И. И. Генетические аспекты сахарного диабета. Сахарный диабет. 2000; 1:2–10.
  3. Беленков Ю. Н, Мареев В. Ю, Агеев Ф. Т. Медикаментозные пути улучшения прогноза больных хронической сердечной недостаточностью. – М:, Инсайт. 1997, – 69–72.
  4. Brophy J. M, Deslauriers G, Rouleau J. L. Long-term prognosis ofpatients presenting to the emergency room with decompensated congestiveheart failure. Can J Cardiol. 1994; 10 (5):543‑547.
  5. Беленков Ю. Н, Мареев В. Ю. Агеев Ф. Т. Эпидемиологические исследования сердечной недостаточности: состояние вопроса. Consilium medicum. 2002; 4 (3):112‑114.
  6. Ferrari LA. Mancini M, Celentano A et al. Early changes of the arterial carotid wall in hyperinsulinemia, hypertriglycermia, versus hypercliolesterolemia. Atherosclerosis. 2003; 171 (2):303‑309.
  7. Sowers JR, Sowers PS, Peuler JD. Role of insulin resistance and hyperinsulinemia in developmant of hypertension and atherosclerosis. J Lab Clin Med. 1994; 123 (5):647‑652.
  8. Després JP, Lamarche B, Mauriège P et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996; 334 (15):952‑957.
  9. Bartnik M, Rydén L, Ferrari R et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. Eur Heart J. 2004; 25 (21):1880–1890.
  10. King GL, Goodman AD, Buzney S et al. Reseptors and insulin-like growth factors on cells from bovine retinal capillaries and aorta. J Clin Invest. 1985; 75 (3):1028–1036.
  11. Bakris GL, Pedant CE, Walsh MF et al. Analogy between endothelial / mesangial cell and endotelial / vascular smooth muscle cell interactions: role of growth factors and mechanotransduction. In Endocrinology of the Vasculature. Sowers J. R, Ed Totowa, N. J, Humana Press, 1996. – p 341‑355.
  12. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991; 14 (3):173‑194.
  13. Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total cardiovascular disease mortality in middle-aged men. JAMA. 2002; 288 (21):2709–2716.
  14. Nieves DJ, Cnop M, Retzlaff B et al. The atherogenic lipoprotein profale associated with ibesity and insulin resistance is largely attributable to intra-abdominal fat. Diabetes. 2003; 52 (1):172‑179.
  15. Rocchini AP. Insulin resistance, obesity and hypertension. J Nutr. 1995; 125 (6 Suppl):1718S-1724S.
  16. Igahi T, Itoh H, Suga S et al. Insulin supresses endotelial-secretion of C-type natriuretic peptide, a novel endotelium-derived relaxing peptide. Diabetes. 1996; 45 (Suppl 3):S62-64.
  17. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonilureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352 (9131):837‑853.
  18. Khaw K. T,Wareham N, Luben R et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european nutrition (EPIC-Norfolk). BMJ. 2001; 322 (7277):15–18.
  19. Doehner W, Rauchhaus M, Ponikowski P et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol. 2005; 46 (6):1019–1026.
  20. DeFronzo R, Tobin J, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J  Physiol. 1979; 237 (3):E214-223.
  21. Shen SW, Reaven GM, Farquhar JW. Comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes. J Clin Invest. 1970; 49 (12):2151–2160.
  22. Harano Y, Ohgaku S, Hidaka H et al. Glucose, insulin and somatostatin infusion for the determination of insulin sensitivity. J Clin Endocrinol Metab. 1977; 45 (5):1124–1127.
  23. Ferrannini E. Physiological and metabolic consequences of obesity. Metabolism. 1995; 44 (9 Suppl 3):7–15.
  24. Seltzer HS, Allen EW, Herron AL Jr, Brennan MT. Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbonhydrate intolerance in mild diabetes mellitus. J Clin Invest. 1967; 46 (3):323‑335.
  25. Диденко В. А. Метаболический синдром Х: история вопроса и этиопатогенез. Лабораторная медицина. 1999; 2:49–57.
  26. Зимин Ю. В. Происхождение, диагностическая концепция и клиническое значение синдрома инсулинорезистентности или метаболического синдрома Х. Кардиология. 1998; 38 (6):71–81.
  27. Mari A. Assessment of insulin sensitivity with minimal model: role of model assumptions. Am J Physiol. 1997; 272 (5 Pt 1):E925-934.
  28. World Health Organization: Report of a WHO Consultation: Definition, Diagnosis and Classification of Diabetes Mellitus and ins Complications. Geneva, World Health Organization,1999. / philip.home / who_dmc.htm
  29. Caro JF. Clinical review 26: Insulin resistance in obese and nonobese man. J Clin Endocrinol Metab. 1991; 73 (4):691‑695.
  30. Pacini G, Bergman RN. MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test. Comput Methods Programs Biomed. 1986; 23 (2):113‑122.
  31. Bergman RN, Finegood DT, Ader M. Assessment of insulin sensitivity in vivo. Endocr Rev. 1985; 6 (1):45–86.
  32. Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest. 1981; 68 (6):1456–1467.
  33. Matthews DR, Hosker JP, Rudenski AS et al. Homeostatis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28 (7):412‑419.
  34. Алишева Е. К, Красильникова Е. И, Шляхто Е. В. Методы диагностики инсулинорезистентности.Артериальная гипертензия. 2002; 1:29–34.
  35. Bhatt DL, Chew DP, Grines C et al. Peroxisome proliferator-activated receptor gamma agonists for the Prevention of Adverse events following percutaneous coronary Revascularization--results of the PPAR study. Am Heart J. 2007; 154 (1):137‑143.
  36. Eurich DT, McAlister FA, Blackburn DF et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ. 2007; 335 (7618):497.
  37. Vantrimpont P, Rouleau JL, Wun CC et al. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. J Am Coll Cardiol. 1997; 29 (2):229‑236.
  38. Gerstein HC, Swedberg K, Carlsson J et al. CHARM Program Investigators. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Arch Intern Med. 2008; 168 (15):1699–1704.

To access this material please log in or register

Register Authorize
Ru En